Lymphopenia in sepsis-an acquired immunodeficiency?
Immunol Cell Biol
; 2022 Dec 05.
Article
in English
| MEDLINE | ID: covidwho-2152730
ABSTRACT
Sepsis is a global health priority, yet effective host-directed targeted therapies have not been identified outside of the setting of COVID-19. Lymphopenia occurs in up to ~52% of patients with sepsis and is associated with a higher mortality at both 30 and 100 days. In COVID-19, the presence of lymphopenia correlates with intensive care unit (ICU) admission, acute respiratory distress syndrome (ARDS) and death. The mechanisms underpinning lymphopenic sepsis remain unknown, and while high rates of lymphocyte apoptosis have been implicated, the relative contributions of cellular trafficking to inflamed tissues and reduction in lymphopoiesis require investigation. Further delineation of these underlying mechanisms holds the potential to open new avenues for the development of host-directed therapies in lymphopenic sepsis. These may include recombinant cytokines (e.g. IL-7), monoclonal antibodies (e.g. anti-IL-1, anti-PD-1) and siRNA (e.g. targeting IL-10, TGFß). Applying the frontier tools of translational cellular and genomic medicine to understand lymphopenia in the setting of critical infections holds the potential to significantly reduce the excessive global burden of sepsis.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
Imcb.12611
Similar
MEDLINE
...
LILACS
LIS